SEC Tracker
Get the app
PYXS · XBRL financial data

Pyxis Oncology financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PYXS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue——16,1460*0*0*—2,8200*11,038*——
Cost of revenue——4750*0*0*———year only——
Research and development14,68711,607*13,02913,95317,74114,024*17,04417,13317,80821,711*19,98316,057
General and administrative10,6676,160*8,2476,0796,0135,081*5,8705,4375,6535,234*4,3779,933
Total operating expenses25,35417,767*————22,91422,570——24,36025,990
Operating income (loss)(25,354)(17,767)*(5,605)(20,032)(23,754)(40,069)*(22,914)(19,750)(23,461)(18,295)*(24,360)(25,990)
Interest income227153*26238719487*8499242225*21861
Income tax expense (benefit)—————year only—2830*1,103*—0
Net income (loss)(23,049)(15,597)*(3,256)(17,301)(21,203)(35,571)*(21,158)(18,354)(22,003)(18,106)*(23,272)(25,346)
Earnings per share, basic USD per share(0.56)(0.35)*(0.06)(0.29)(0.35)(0.58)*(0.35)(0.30)(0.35)(0.29)*(0.37)(0.40)
Earnings per share, diluted USD per share(0.56)(0.35)*(0.06)(0.29)(0.35)(0.58)*(0.35)(0.30)(0.35)(0.29)*(0.37)(0.40)
Weighted average shares, basic thousands of shares41,33244,430*51,28960,49660,71561,228*61,04961,91962,55763,021*63,47063,992
Weighted average shares, diluted thousands of shares41,33244,430*51,28960,49660,71561,228*61,04961,91962,55763,021*63,47063,992

Balance sheet

CSV

Fiscal quarters (PYXS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents14,7159,66427,96725,07412,05619,47312,75910,7338,91915,4225,76618,855
Marketable securities118,252109,634129,060130,650132,762107,45892,67378,21167,33751,43535,25214,141
Accounts receivable——8,000————3,000————
Prepaid and other current assets—3,834———4,037———3,776——
Total current assets139,094124,604172,379161,038148,868132,440111,87199,95683,07372,10545,57236,734
Property and equipment, net12,17511,87211,33311,06910,3969,8999,4038,9248,4607,9977,5387,237
Right-of-use asset13,12912,94212,778——12,24212,04911,84711,63711,41811,19010,951
Total assets186,692173,726220,220208,389195,311157,181135,867123,215105,60491,52064,30054,922
Accounts payable3,3103,8962,2935,4704,8704,8592,8469,4129,75610,8854,9893,269
Accrued liabilities16,62912,97110,82810,08914,05711,37110,0766,6987,9968,5549,78612,381
Total current liabilities28,33225,75914,14116,89720,32017,68014,43017,67819,38221,13116,53227,474
Lease liability, non-current20,41420,09919,75919,39919,03018,65018,25417,83217,40016,95816,49716,008
Total liabilities48,74648,02236,06438,59541,63136,43032,76435,57236,82538,11233,03243,482
Accumulated deficit(270,628)(286,225)(289,481)(306,782)(327,985)(363,556)(384,714)(403,068)(425,071)(443,177)(466,449)(491,795)
Total stockholders' equity137,946125,704184,156169,794153,680120,751103,10387,64368,77953,40831,26811,440
Total liabilities and equity186,692173,726220,220208,389195,311157,181135,867123,215105,60491,52064,30054,922
Common shares outstanding (cover page) thousands of shares44,32358,13358,88858,94259,46661,59061,94862,01862,26462,83163,35583,408

Cash flows

CSV

Fiscal quarters (PYXS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(23,049)(15,597)*(3,256)(17,301)(21,203)(35,571)*(21,158)(18,354)(22,003)(18,106)*(23,272)(25,346)
Stock-based compensation5,179*3,215*4,3202,871*2,981*2,773*3,6313,015*3,073*2,082*1,2105,528*
Depreciation and amortization523*690*1,116585*731*550*552535*527*2,897*459301*
Net cash from operating activities(17,583)*(15,254)*(20,710)(3,007)*(14,665)*(19,290)*(22,535)(17,263)*(13,277)*(10,427)*(26,000)(18,206)*
Purchases of property and equipment61*0*2370*0*0*———0*——
Net cash from investing activities6,571*10,228*(18,498)4*(8)*26,657*15,82115,304*11,471*16,261*16,36921,301*
Net cash from financing activities(171)*(25)*57,511110*1,655*50*0(67)*(8)*669*(25)9,994*
Net change in cash(11,183)*(5,051)*18,303(2,893)*(13,018)*7,417*(6,714)(2,026)*(1,814)*6,503*(9,656)13,089*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Pyxis Oncology18,855not reported(18,206)*83.4M1.8 quarters 10-QJun 30, 2026
Veru23,880not reported(5,467)*17.1M4.4 quarters 10-QJun 30, 2026
Whitehawk Therapeutics85,2340(14,529)*57.0M13.1 quarters 10-QJun 30, 2026
Lifevantage14,92042,377*4,767*12.5M— 10-KJun 30, 2026
Medicinova25,416458(1,920)*49.2M13.2 quarters 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings23,370not reported(29,626)*19.3M4.0 quarters 10-QJun 30, 2026
PDS Biotechnology5,596not reported(2,793)*56.0M2.0 quarters 10-QJun 30, 2026
Sutro Biopharma54,3359,839(38,290)*16.6M4.3 quarters 10-QJun 30, 2026
Seres Therapeutics15,594736(22,394)*9.9M0.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.